| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.877 | 0.004 | 0.892 | Aldehyde oxidase inhibitor | 0.719 0.007 DBMET01451 0.892 0.003 DBMET01449 | DBMET01449 | |
| 0.702 | 0.005 | 0.702 | Histamine release inhibitor | 0.48 0.036 DBMET01451 0.65 0.007 DBMET01449 | ||
| 0.67 | 0.005 | 0.67 | Superoxide dismutase inhibitor | 0.326 0.042 DBMET01451 0.473 0.016 DBMET01449 | ||
| 0.613 | 0.009 | 0.613 | 5 Hydroxytryptamine release inhibitor | 0.397 0.08 DBMET01451 0.556 0.018 DBMET01449 | ||
| 0.604 | 0.003 | 0.604 | Alcohol oxidase inhibitor | 0.215 0.006 DBMET01451 0.378 0.004 DBMET01449 | ||
| 0.625 | 0.033 | 0.64 | Caspase 9 stimulant | 0.505 0.058 DBMET01451 0.64 0.031 DBMET01449 | DBMET01449 | |
| 0.578 | 0.003 | 0.725 | Cystathionine beta-synthase inhibitor | 0.638 0.003 DBMET01451 0.725 0.002 DBMET01449 | DBMET01449 | |
| 0.581 | 0.015 | 0.581 | 12-Lipoxygenase inhibitor | 0.322 0.068 DBMET01451 0.424 0.033 DBMET01449 | ||
| 0.563 | 0.002 | 0.579 | Keratolytic | 0.272 0.004 DBMET01451 0.579 0.002 DBMET01449 | DBMET01449 | |
| 0.561 | 0.013 | 0.561 | Lipoxygenase inhibitor | 0.287 0.078 DBMET01451 0.422 0.032 DBMET01449 | ||
| 0.513 | 0.006 | 0.669 | Topoisomerase II inhibitor | 0.512 0.006 DBMET01451 0.669 0.004 DBMET01449 | DBMET01449 | |
| 0.529 | 0.028 | 0.584 | Cholesterol antagonist | 0.584 0.021 DBMET01451 0.556 0.024 DBMET01449 | DBMET01451 | |
| 0.557 | 0.059 | 0.675 | Apoptosis agonist | 0.62 0.045 DBMET01451 0.675 0.035 DBMET01449 | DBMET01449 | |
| 0.497 | 0.01 | 0.497 | Peroxidase inhibitor | 0.4 0.02 DBMET01451 0.485 0.011 DBMET01449 | ||
| 0.52 | 0.035 | 0.632 | Antibacterial | 0.632 0.015 DBMET01451 0.537 0.031 DBMET01449 | DBMET01451 | |
| 0.484 | 0.003 | 0.484 | Carbonic anhydrase III inhibitor | 0.162 0.024 DBMET01451 0.27 0.007 DBMET01449 | ||
| 0.509 | 0.043 | 0.584 | Transcription factor NF kappa B inhibitor | 0.457 0.051 DBMET01451 0.584 0.033 DBMET01449 | DBMET01449 | |
| 0.461 | 0.006 | 0.463 | 5 Hydroxytryptamine uptake stimulant | 0.433 0.009 DBMET01451 0.463 0.006 DBMET01449 | DBMET01449 | |
| 0.454 | 0.003 | 0.454 | Histidine decarboxylase inhibitor | 0.207 0.012 DBMET01451 0.358 0.005 DBMET01449 | ||
| 0.492 | 0.042 | 0.492 | 15-Lipoxygenase inhibitor | 0.285 0.141 DBMET01451 0.491 0.042 DBMET01449 | ||
| 0.454 | 0.005 | 0.454 | Aldehyde dehydrogenase inhibitor | 0.25 0.018 DBMET01451 0.44 0.005 DBMET01449 | ||
| 0.454 | 0.009 | 0.454 | Dual specificity phosphatase inhibitor | 0.286 0.031 DBMET01451 0.385 0.016 DBMET01449 | ||
| 0.438 | 0.006 | 0.441 | NOS3 expression enhancer | 0.153 0.069 DBMET01451 0.441 0.006 DBMET01449 | DBMET01449 | |
| 0.449 | 0.022 | 0.449 | Free radical scavenger | 0.359 0.037 DBMET01451 0.446 0.022 DBMET01449 | ||
| 0.432 | 0.007 | 0.432 | Alpha-N-acetylglucosaminidase inhibitor | 0.293 0.017 DBMET01451 0.37 0.01 DBMET01449 | ||
| 0.436 | 0.014 | 0.436 | Interleukin agonist | 0.281 0.058 DBMET01451 0.372 0.024 DBMET01449 | ||
| 0.438 | 0.018 | 0.438 | DNA synthesis inhibitor | 0.387 0.023 DBMET01451 0.407 0.021 DBMET01449 | ||
| 0.458 | 0.039 | 0.458 | GABA C receptor rho-3 antagonist | 0.426 0.051 DBMET01451 0.432 0.048 DBMET01449 | ||
| 0.407 | 0.004 | 0.407 | Carbonic anhydrase VI inhibitor | 0.108 0.035 DBMET01451 0.265 0.008 DBMET01449 | ||
| 0.407 | 0.004 | 0.407 | Porphobilinogen synthase inhibitor | 0.234 0.009 DBMET01451 0.317 0.005 DBMET01449 | ||
| 0.427 | 0.024 | 0.472 | Hypoxia-inducible factor 1 alpha inhibitor | 0.352 0.044 DBMET01451 0.472 0.017 DBMET01449 | DBMET01449 | |
| 0.431 | 0.03 | 0.449 | Antioxidant | 0.41 0.033 DBMET01451 0.449 0.027 DBMET01449 | DBMET01449 | |
| 0.4 | 0.003 | 0.4 | Creatine kinase inhibitor | 0.283 0.004 DBMET01451 0.295 0.004 DBMET01449 | ||
| 0.399 | 0.005 | 0.399 | 5-Lipoxygenase inhibitor | 0.22 0.021 DBMET01451 0.26 0.014 DBMET01449 | ||
| 0.392 | 0.004 | 0.406 | Hexokinase inhibitor | 0.23 0.022 DBMET01451 0.406 0.004 DBMET01449 | DBMET01449 | |
| 0.376 | 0.003 | 0.376 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.243 0.006 DBMET01451 0.342 0.004 DBMET01449 | ||
| 0.413 | 0.046 | 0.413 | Antithrombotic | 0.28 0.103 DBMET01451 0.369 0.058 DBMET01449 | ||
| 0.377 | 0.011 | 0.377 | Tyrosine 3 hydroxylase inhibitor | 0.271 0.05 DBMET01451 0.31 0.029 DBMET01449 | ||
| 0.387 | 0.024 | 0.387 | Sigma receptor agonist | 0.141 0.092 DBMET01451 0.28 0.043 DBMET01449 | ||
| 0.402 | 0.044 | 0.595 | Caspase 3 stimulant | 0.334 0.064 DBMET01451 0.595 0.01 DBMET01449 | DBMET01449 | |
| 0.397 | 0.039 | 0.413 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.215 0.091 DBMET01451 0.413 0.035 DBMET01449 | DBMET01449 | |
| 0.367 | 0.012 | 0.367 | Amylase inhibitor | 0.175 0.053 DBMET01451 0.317 0.016 DBMET01449 | ||
| 0.355 | 0.005 | 0.449 | Xanthine oxidase inhibitor | 0.237 0.014 DBMET01451 0.449 0.004 DBMET01449 | DBMET01449 | |
| 0.374 | 0.025 | 0.452 | Transcription factor STAT3 inhibitor | 0.244 0.088 DBMET01451 0.452 0.011 DBMET01449 | DBMET01449 | |
| 0.418 | 0.069 | 0.418 | Calcium channel L-type activator | 0.372 0.101 DBMET01451 0.416 0.071 DBMET01449 | ||
| 0.358 | 0.011 | 0.382 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.382 0.009 DBMET01451 0.358 0.011 DBMET01449 | DBMET01451 | |
| 0.352 | 0.007 | 0.352 | GABA C receptor agonist | 0.224 0.017 DBMET01451 0.292 0.01 DBMET01449 | ||
| 0.356 | 0.012 | 0.356 | Protein-tyrosine phosphatase inhibitor | 0.303 0.018 DBMET01451 0.336 0.014 DBMET01449 | ||
| 0.365 | 0.029 | 0.445 | Transcription factor STAT inhibitor | 0.209 0.125 DBMET01451 0.445 0.012 DBMET01449 | DBMET01449 | |
| 0.341 | 0.006 | 0.341 | Succinate dehydrogenase inhibitor | 0.333 0.007 DBMET01451 0.333 0.007 DBMET01449 | ||
| 0.348 | 0.021 | 0.348 | Dual specificity phosphatase 3 inhibitor | 0.187 0.069 DBMET01451 0.28 0.032 DBMET01449 | ||
| 0.329 | 0.002 | 0.329 | DOPA decarboxylase inhibitor | 0.189 0.008 DBMET01451 0.27 0.003 DBMET01449 | ||
| 0.363 | 0.037 | 0.42 | DNA damaging | 0.177 0.137 DBMET01451 0.42 0.024 DBMET01449 | DBMET01449 | |
| 0.33 | 0.006 | 0.33 | Carbonic anhydrase XV inhibitor | 0.156 0.029 DBMET01451 0.322 0.006 DBMET01449 | ||
| 0.347 | 0.024 | 0.347 | Anesthetic general | 0.213 0.068 DBMET01449 | ||
| 0.356 | 0.033 | 0.356 | Amyloid beta aggregation inhibitor | 0.151 0.107 DBMET01451 0.25 0.058 DBMET01449 | ||
| 0.357 | 0.035 | 0.359 | Sodium/bile acid cotransporter inhibitor | 0.349 0.04 DBMET01451 0.359 0.035 DBMET01449 | DBMET01449 | |
| 0.346 | 0.024 | 0.346 | RNA-directed DNA polymerase inhibitor | 0.288 0.034 DBMET01451 0.312 0.029 DBMET01449 | ||
| 0.368 | 0.047 | 0.407 | Vasodilator, coronary | 0.207 0.176 DBMET01451 0.407 0.033 DBMET01449 | DBMET01449 | |
| 0.355 | 0.037 | 0.359 | Hypoglycemic | 0.345 0.039 DBMET01451 0.359 0.036 DBMET01449 | DBMET01449 | |
| 0.329 | 0.015 | 0.451 | Monophenol monooxygenase inhibitor | 0.451 0.009 DBMET01451 0.318 0.016 DBMET01449 | DBMET01451 | |
| 0.316 | 0.006 | 0.479 | Topoisomerase II alpha inhibitor | 0.395 0.005 DBMET01451 0.479 0.004 DBMET01449 | DBMET01449 | |
| 0.335 | 0.029 | 0.335 | Cyclic AMP phosphodiesterase inhibitor | 0.169 0.124 DBMET01451 0.333 0.03 DBMET01449 | ||
| 0.37 | 0.066 | 0.39 | Vasodilator, peripheral | 0.39 0.058 DBMET01449 | DBMET01449 | |
| 0.314 | 0.021 | 0.331 | Mcl-1 antagonist | 0.207 0.052 DBMET01451 0.331 0.018 DBMET01449 | DBMET01449 | |
| 0.334 | 0.043 | 0.334 | Antiamyloidogenic | 0.262 0.066 DBMET01449 | ||
| 0.293 | 0.005 | 0.293 | Alcohol dehydrogenase inhibitor | 0.133 0.027 DBMET01451 0.268 0.006 DBMET01449 | ||
| 0.309 | 0.026 | 0.309 | Non-steroidal antiinflammatory agent | 0.187 0.082 DBMET01451 0.249 0.043 DBMET01449 | ||
| 0.29 | 0.011 | 0.29 | UDP-glucose 4-epimerase inhibitor | 0.185 0.02 DBMET01451 0.243 0.014 DBMET01449 | ||
| 0.284 | 0.005 | 0.284 | Potassium channel (Ca-activated) activator | 0.101 0.055 DBMET01451 0.202 0.014 DBMET01449 | ||
| 0.282 | 0.004 | 0.282 | HIV-1 integrase (Overall Integration) inhibitor | 0.19 0.014 DBMET01451 0.265 0.004 DBMET01449 | ||
| 0.318 | 0.043 | 0.379 | Pyruvate kinase inhibitor | 0.212 0.075 DBMET01451 0.379 0.025 DBMET01449 | DBMET01449 | |
| 0.293 | 0.019 | 0.293 | Phospholipase C inhibitor | 0.192 0.049 DBMET01451 0.256 0.024 DBMET01449 | ||
| 0.378 | 0.104 | 0.394 | Cyclophilin D inhibitor | 0.394 0.094 DBMET01451 0.341 0.129 DBMET01449 | DBMET01451 | |
| 0.335 | 0.061 | 0.37 | Calcium channel activator | 0.33 0.064 DBMET01451 0.37 0.038 DBMET01449 | DBMET01449 | |
| 0.278 | 0.004 | 0.278 | Glutamate decarboxylase inhibitor | 0.198 0.007 DBMET01451 0.219 0.005 DBMET01449 | ||
| 0.293 | 0.02 | 0.294 | Neurotrophic factor enhancer | 0.222 0.057 DBMET01451 0.294 0.02 DBMET01449 | DBMET01449 | |
| 0.407 | 0.135 | 0.407 | Antiinflammatory | 0.269 0.247 DBMET01451 0.398 0.14 DBMET01449 | ||
| 0.333 | 0.065 | 0.333 | Apoptosis antagonist | 0.33 0.066 DBMET01449 | ||
| 0.267 | 0.004 | 0.267 | GABA aminotransferase inhibitor | 0.24 0.004 DBMET01451 0.194 0.004 DBMET01449 | ||
| 0.323 | 0.062 | 0.323 | Spasmolytic | 0.232 0.099 DBMET01449 | ||
| 0.273 | 0.014 | 0.593 | Topoisomerase I inhibitor | 0.593 0.003 DBMET01451 0.372 0.006 DBMET01449 | DBMET01451 | |
| 0.295 | 0.037 | 0.316 | Gastrin inhibitor | 0.221 0.117 DBMET01451 0.316 0.023 DBMET01449 | DBMET01449 | |
| 0.278 | 0.025 | 0.292 | Melanin inhibitor | 0.292 0.023 DBMET01451 0.272 0.026 DBMET01449 | DBMET01451 | |
| 0.259 | 0.006 | 0.506 | HIV-1 integrase (3'-Processing) inhibitor | 0.506 0.003 DBMET01451 0.294 0.005 DBMET01449 | DBMET01451 | |
| 0.278 | 0.026 | 0.278 | Lipocortins synthesis antagonist | 0.234 0.039 DBMET01451 0.261 0.03 DBMET01449 | ||
| 0.274 | 0.024 | 0.291 | Interferon gamma antagonist | 0.237 0.031 DBMET01451 0.291 0.021 DBMET01449 | DBMET01449 | |
| 0.264 | 0.014 | 0.264 | Chelator | 0.115 0.058 DBMET01451 0.222 0.021 DBMET01449 | ||
| 0.273 | 0.024 | 0.284 | Insulin sensitizer | 0.2 0.073 DBMET01451 0.284 0.02 DBMET01449 | DBMET01449 | |
| 0.252 | 0.006 | 0.252 | AMP-activated protein kinase stimulant | 0.152 0.027 DBMET01451 0.185 0.013 DBMET01449 | ||
| 0.267 | 0.024 | 0.267 | Lipid peroxidase inhibitor | 0.157 0.064 DBMET01451 0.255 0.026 DBMET01449 | ||
| 0.242 | 0.006 | 0.242 | TRPA1 agonist | 0.155 0.027 DBMET01451 0.173 0.018 DBMET01449 | ||
| 0.273 | 0.037 | 0.273 | DNA methylase inhibitor | 0.165 0.105 DBMET01451 0.24 0.054 DBMET01449 | ||
| 0.243 | 0.007 | 0.243 | Triose-phosphate isomerase inhibitor | 0.173 0.015 DBMET01451 0.222 0.009 DBMET01449 | ||
| 0.254 | 0.02 | 0.254 | NADPH oxidase inhibitor | 0.142 0.06 DBMET01451 0.232 0.025 DBMET01449 | ||
| 0.272 | 0.038 | 0.272 | DNA methyltransferase I inhibitor | 0.187 0.076 DBMET01451 0.247 0.048 DBMET01449 | ||
| 0.242 | 0.01 | 0.242 | Cyclooxygenase 3 inhibitor | 0.171 0.033 DBMET01451 0.197 0.02 DBMET01449 | ||
| 0.248 | 0.017 | 0.248 | Protein-tyrosine phosphatase 1B inhibitor | 0.228 0.022 DBMET01451 0.246 0.017 DBMET01449 | ||
| 0.238 | 0.007 | 0.275 | HIV-1 integrase (Strand Transfer) inhibitor | 0.225 0.008 DBMET01451 0.275 0.005 DBMET01449 | DBMET01449 | |
| 0.293 | 0.063 | 0.293 | Insulysin inhibitor | 0.207 0.147 DBMET01451 0.287 0.067 DBMET01449 | ||
| 0.239 | 0.01 | 0.239 | Mediator release inhibitor | 0.135 0.036 DBMET01449 | ||
| 0.232 | 0.004 | 0.242 | Topoisomerase II beta inhibitor | 0.101 0.009 DBMET01451 0.242 0.003 DBMET01449 | DBMET01449 | |
| 0.253 | 0.025 | 0.253 | Heat shock protein 90 alpha antagonist | 0.131 0.11 DBMET01451 0.201 0.048 DBMET01449 | ||
| 0.236 | 0.009 | 0.272 | Uric acid excretion stimulant | 0.175 0.017 DBMET01451 0.272 0.005 DBMET01449 | DBMET01449 | |
| 0.233 | 0.008 | 0.233 | Glutamate dehydrogenase inhibitor | 0.152 0.015 DBMET01451 0.226 0.008 DBMET01449 | ||
| 0.239 | 0.015 | 0.239 | Mannose-6-phosphate isomerase inhibitor | 0.169 0.05 DBMET01451 0.207 0.027 DBMET01449 | ||
| 0.233 | 0.012 | 0.233 | Toll-Like receptor 2 antagonist | 0.179 0.034 DBMET01451 0.23 0.013 DBMET01449 | ||
| 0.237 | 0.02 | 0.264 | Cholesterol synthesis inhibitor | 0.204 0.026 DBMET01451 0.264 0.016 DBMET01449 | DBMET01449 | |
| 0.227 | 0.011 | 0.227 | NMDA receptor antagonist | 0.17 0.019 DBMET01449 | ||
| 0.256 | 0.047 | 0.256 | Peptidyltransferase inhibitor | 0.199 0.1 DBMET01451 0.25 0.05 DBMET01449 | ||
| 0.211 | 0.003 | 0.211 | Ca2+-transporting ATPase inhibitor | 0.196 0.004 DBMET01451 0.208 0.003 DBMET01449 | ||
| 0.218 | 0.01 | 0.218 | MAP3K9 inhibitor | |||
| 0.222 | 0.016 | 0.222 | Arachidonic acid antagonist | 0.201 0.032 DBMET01451 0.214 0.021 DBMET01449 | ||
| 0.257 | 0.05 | 0.304 | Nitric oxide antagonist | 0.303 0.04 DBMET01451 0.304 0.04 DBMET01449 | DBMET01449 | |
| 0.267 | 0.061 | 0.27 | Vasodilator | 0.27 0.059 DBMET01449 | DBMET01449 | |
| 0.224 | 0.02 | 0.26 | Alkylator | 0.115 0.073 DBMET01451 0.26 0.015 DBMET01449 | DBMET01449 | |
| 0.352 | 0.149 | 0.352 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.305 0.206 DBMET01451 0.346 0.156 DBMET01449 | ||
| 0.234 | 0.031 | 0.25 | Protein kinase stimulant | 0.25 0.026 DBMET01451 0.243 0.028 DBMET01449 | DBMET01451 | |
| 0.246 | 0.044 | 0.298 | Hepatoprotectant | 0.284 0.034 DBMET01451 0.298 0.03 DBMET01449 | DBMET01449 | |
| 0.223 | 0.022 | 0.223 | Adenylate cyclase inhibitor | 0.093 0.091 DBMET01451 0.196 0.026 DBMET01449 | ||
| 0.21 | 0.011 | 0.21 | Photosensitizer | 0.128 0.048 DBMET01451 0.195 0.014 DBMET01449 | ||
| 0.229 | 0.03 | 0.229 | Phospholipase A2 inhibitor | 0.153 0.071 DBMET01451 0.221 0.033 DBMET01449 | ||
| 0.199 | 0.004 | 0.199 | Xanthine dehydrogenase inhibitor | 0.116 0.012 DBMET01451 0.196 0.004 DBMET01449 | ||
| 0.215 | 0.022 | 0.215 | Catenin beta inhibitor | 0.17 0.067 DBMET01451 0.203 0.03 DBMET01449 | ||
| 0.209 | 0.019 | 0.209 | Expectorant | 0.124 0.048 DBMET01451 0.209 0.019 DBMET01449 | ||
| 0.201 | 0.016 | 0.227 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.172 0.021 DBMET01451 0.227 0.012 DBMET01449 | DBMET01449 | |
| 0.205 | 0.021 | 0.205 | Ferrochelatase inhibitor | 0.129 0.048 DBMET01451 0.181 0.027 DBMET01449 | ||
| 0.197 | 0.013 | 0.251 | Estrogen antagonist | 0.139 0.029 DBMET01451 0.251 0.008 DBMET01449 | DBMET01449 | |
| 0.19 | 0.008 | 0.19 | Phenylalanine 4-hydroxylase inhibitor | 0.123 0.017 DBMET01451 0.167 0.01 DBMET01449 | ||
| 0.27 | 0.089 | 0.27 | Immunostimulant | 0.164 0.143 DBMET01451 0.255 0.094 DBMET01449 | ||
| 0.188 | 0.009 | 0.198 | Heat shock protein 70 antagonist | 0.153 0.04 DBMET01451 0.198 0.007 DBMET01449 | DBMET01449 | |
| 0.186 | 0.009 | 0.196 | Estrogen receptor alpha antagonist | 0.09 0.035 DBMET01451 0.196 0.008 DBMET01449 | DBMET01449 | |
| 0.202 | 0.025 | 0.33 | DNA intercalator | 0.154 0.041 DBMET01451 0.33 0.01 DBMET01449 | DBMET01449 | |
| 0.187 | 0.011 | 0.196 | Estrogen receptor beta antagonist | 0.128 0.024 DBMET01451 0.196 0.01 DBMET01449 | DBMET01449 | |
| 0.181 | 0.005 | 0.181 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.158 0.006 DBMET01451 0.174 0.005 DBMET01449 | ||
| 0.177 | 0.002 | 0.177 | ATP citrate lysase inhibitor | 0.052 0.007 DBMET01451 0.092 0.004 DBMET01449 | ||
| 0.213 | 0.04 | 0.213 | Diuretic | 0.161 0.068 DBMET01449 | ||
| 0.303 | 0.132 | 0.303 | MAP kinase kinase 6 inhibitor | 0.234 0.211 DBMET01449 | ||
| 0.194 | 0.025 | 0.194 | CF transmembrane conductance regulator agonist | 0.192 0.026 DBMET01449 | ||
| 0.181 | 0.012 | 0.181 | NADH dehydrogenase inhibitor | 0.14 0.02 DBMET01451 0.171 0.014 DBMET01449 | ||
| 0.185 | 0.016 | 0.185 | Carbonic anhydrase XIII inhibitor | 0.065 0.063 DBMET01451 0.148 0.022 DBMET01449 | ||
| 0.192 | 0.025 | 0.215 | Interleukin 4 antagonist | 0.139 0.06 DBMET01451 0.215 0.019 DBMET01449 | DBMET01449 | |
| 0.187 | 0.023 | 0.491 | Antineoplastic antibiotic | 0.491 0.004 DBMET01451 0.189 0.023 DBMET01449 | DBMET01451 | |
| 0.2 | 0.038 | 0.2 | Heat shock protein 90 antagonist | 0.179 0.049 DBMET01449 | ||
| 0.175 | 0.013 | 0.175 | GABA C receptor rho-1 antagonist | 0.125 0.036 DBMET01451 0.133 0.03 DBMET01449 | ||
| 0.175 | 0.015 | 0.175 | DNA repair enzyme inhibitor | 0.172 0.017 DBMET01449 | ||
| 0.178 | 0.018 | 0.178 | GABA C receptor antagonist | 0.14 0.036 DBMET01451 0.164 0.023 DBMET01449 | ||
| 0.164 | 0.005 | 0.186 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.106 0.009 DBMET01451 0.186 0.004 DBMET01449 | DBMET01449 | |
| 0.165 | 0.005 | 0.165 | CDC25B inhibitor | 0.132 0.009 DBMET01451 0.156 0.005 DBMET01449 | ||
| 0.178 | 0.02 | 0.19 | Mucolytic | 0.132 0.044 DBMET01451 0.19 0.016 DBMET01449 | DBMET01449 | |
| 0.191 | 0.034 | 0.191 | GABA C receptor rho-2 antagonist | 0.162 0.058 DBMET01451 0.167 0.053 DBMET01449 | ||
| 0.166 | 0.011 | 0.166 | Anabolic | 0.151 0.017 DBMET01451 0.164 0.012 DBMET01449 | ||
| 0.164 | 0.009 | 0.164 | Potassium channel large-conductance Ca-activated activator | 0.068 0.047 DBMET01451 0.121 0.016 DBMET01449 | ||
| 0.213 | 0.061 | 0.213 | I kappa B kinase epsilon inhibitor | 0.195 0.075 DBMET01449 | ||
| 0.164 | 0.012 | 0.179 | Macrophage migration inhibitory factor inhibitor | 0.07 0.066 DBMET01451 0.179 0.01 DBMET01449 | DBMET01449 | |
| 0.28 | 0.128 | 0.376 | Immunosuppressant | 0.376 0.073 DBMET01449 | DBMET01449 | |
| 0.188 | 0.038 | 0.188 | Alkaline phosphatase inhibitor | 0.175 0.045 DBMET01449 | ||
| 0.186 | 0.036 | 0.186 | Cell wall synthesis inhibitor | 0.115 0.108 DBMET01451 0.181 0.039 DBMET01449 | ||
| 0.208 | 0.059 | 0.275 | P-glycoprotein inhibitor | 0.164 0.096 DBMET01451 0.275 0.034 DBMET01449 | DBMET01449 | |
| 0.15 | 0.003 | 0.15 | Retinoid X alpha receptor agonist | 0.061 0.011 DBMET01451 0.113 0.004 DBMET01449 | ||
| 0.153 | 0.01 | 0.179 | Ornithine decarboxylase inhibitor | 0.148 0.012 DBMET01451 0.179 0.006 DBMET01449 | DBMET01449 | |
| 0.166 | 0.027 | 0.166 | Protein kinase (CK2) inhibitor | 0.085 0.077 DBMET01451 0.134 0.04 DBMET01449 | ||
| 0.145 | 0.008 | 0.145 | Purinergic P2X1 antagonist | 0.103 0.016 DBMET01451 0.134 0.009 DBMET01449 | ||
| 0.142 | 0.004 | 0.142 | Aconitate hydratase inhibitor | 0.103 0.008 DBMET01451 0.132 0.005 DBMET01449 | ||
| 0.16 | 0.023 | 0.17 | Adenylate kinase inhibitor | 0.139 0.031 DBMET01451 0.17 0.02 DBMET01449 | DBMET01449 | |
| 0.147 | 0.013 | 0.16 | CDC25A inhibitor | 0.16 0.011 DBMET01451 0.157 0.012 DBMET01449 | DBMET01451 | |
| 0.178 | 0.044 | 0.178 | Cyclooxygenase 1 inhibitor | 0.153 0.055 DBMET01449 | ||
| 0.185 | 0.052 | 0.185 | ATPase inhibitor | 0.148 0.106 DBMET01451 0.167 0.075 DBMET01449 | ||
| 0.166 | 0.034 | 0.166 | Protein kinase (CK2) alpha inhibitor | 0.145 0.045 DBMET01449 | ||
| 0.167 | 0.038 | 0.175 | Adenylate cyclase stimulant | 0.139 0.083 DBMET01451 0.175 0.03 DBMET01449 | DBMET01449 | |
| 0.135 | 0.006 | 0.135 | CD45 antagonist | 0.059 0.023 DBMET01451 0.107 0.008 DBMET01449 | ||
| 0.293 | 0.165 | 0.293 | DNA directed DNA polymerase inhibitor | 0.221 0.211 DBMET01449 | ||
| 0.139 | 0.01 | 0.201 | HIV-1 integrase inhibitor | 0.201 0.005 DBMET01451 0.126 0.013 DBMET01449 | DBMET01451 | |
| 0.166 | 0.038 | 0.172 | MAP kinase kinase 4 inhibitor | 0.172 0.03 DBMET01451 0.159 0.047 DBMET01449 | DBMET01451 | |
| 0.168 | 0.04 | 0.19 | DNA polymerase I inhibitor | 0.19 0.031 DBMET01451 0.176 0.037 DBMET01449 | DBMET01451 | |
| 0.199 | 0.071 | 0.207 | Histone acetyltransferase inhibitor | 0.207 0.059 DBMET01449 | DBMET01449 | |
| 0.252 | 0.125 | 0.255 | Prostaglandin dehydrogenase inhibitor | 0.255 0.124 DBMET01449 | DBMET01449 | |
| 0.165 | 0.039 | 0.165 | Sphingosine 1-phosphate receptor 5 antagonist | 0.122 0.121 DBMET01451 0.159 0.048 DBMET01449 | ||
| 0.148 | 0.023 | 0.199 | Prolactin inhibitor | 0.13 0.032 DBMET01451 0.199 0.009 DBMET01449 | DBMET01449 | |
| 0.169 | 0.044 | 0.175 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.157 0.06 DBMET01451 0.175 0.037 DBMET01449 | DBMET01449 | |
| 0.145 | 0.021 | 0.145 | Electrolyte absorption antagonist | 0.093 0.068 DBMET01451 0.129 0.03 DBMET01449 | ||
| 0.131 | 0.009 | 0.133 | D-Ala-D-Ala ligase inhibitor | 0.111 0.019 DBMET01451 0.133 0.009 DBMET01449 | DBMET01449 | |
| 0.17 | 0.049 | 0.254 | Tubulin antagonist | 0.14 0.063 DBMET01451 0.254 0.025 DBMET01449 | DBMET01449 | |
| 0.21 | 0.089 | 0.294 | Angiogenesis stimulant | 0.294 0.051 DBMET01451 0.223 0.083 DBMET01449 | DBMET01451 | |
| 0.14 | 0.02 | 0.152 | ABCA1 expression enhancer | 0.088 0.069 DBMET01451 0.152 0.017 DBMET01449 | DBMET01449 | |
| 0.132 | 0.013 | 0.132 | Leukotriene synthesis inhibitor | 0.118 0.017 DBMET01449 | ||
| 0.123 | 0.003 | 0.123 | Retinoid X receptor agonist | 0.07 0.01 DBMET01451 0.098 0.005 DBMET01449 | ||
| 0.172 | 0.054 | 0.172 | Insulin secretagoues | 0.128 0.1 DBMET01451 0.148 0.077 DBMET01449 | ||
| 0.154 | 0.036 | 0.191 | Microtubule formation inhibitor | 0.125 0.055 DBMET01451 0.191 0.022 DBMET01449 | DBMET01449 | |
| 0.222 | 0.105 | 0.231 | 5 Hydroxytryptamine release stimulant | 0.231 0.099 DBMET01449 | DBMET01449 | |
| 0.124 | 0.008 | 0.131 | Estradiol 17 beta-dehydrogenase inhibitor | 0.045 0.028 DBMET01451 0.131 0.007 DBMET01449 | DBMET01449 | |
| 0.137 | 0.021 | 0.137 | Phosphofructokinase-1 inhibitor | 0.094 0.034 DBMET01451 0.123 0.024 DBMET01449 | ||
| 0.13 | 0.015 | 0.19 | Beta tubulin antagonist | 0.051 0.046 DBMET01451 0.19 0.008 DBMET01449 | DBMET01449 | |
| 0.148 | 0.033 | 0.148 | Protein kinase C gamma inhibitor | 0.106 0.067 DBMET01449 | ||
| 0.166 | 0.052 | 0.166 | Hemostatic | 0.152 0.066 DBMET01449 | ||
| 0.128 | 0.014 | 0.128 | Argininosuccinate synthase inhibitor | 0.081 0.025 DBMET01451 0.111 0.017 DBMET01449 | ||
| 0.282 | 0.169 | 0.352 | Alpha-glucosidase inhibitor | 0.352 0.135 DBMET01449 | DBMET01449 | |
| 0.157 | 0.045 | 0.161 | Farnesoid X receptor antagonist | 0.125 0.092 DBMET01451 0.161 0.041 DBMET01449 | DBMET01449 | |
| 0.141 | 0.03 | 0.153 | Beta glucuronidase inhibitor | 0.124 0.042 DBMET01451 0.153 0.024 DBMET01449 | DBMET01449 | |
| 0.128 | 0.019 | 0.128 | Interleukin 5 antagonist | 0.115 0.027 DBMET01449 | ||
| 0.15 | 0.041 | 0.15 | MAO A inhibitor | |||
| 0.112 | 0.004 | 0.112 | Retinoic acid alpha receptor agonist | 0.066 0.007 DBMET01451 0.087 0.005 DBMET01449 | ||
| 0.122 | 0.016 | 0.122 | Thioredoxin reductase inhibitor | 0.097 0.031 DBMET01451 0.119 0.017 DBMET01449 | ||
| 0.225 | 0.118 | 0.338 | Streptokinase A inhibitor | 0.338 0.065 DBMET01451 0.203 0.131 DBMET01449 | DBMET01451 | |
| 0.135 | 0.03 | 0.194 | Electron transport complex I inhibitor | 0.194 0.009 DBMET01451 0.106 0.071 DBMET01449 | DBMET01451 | |
| 0.135 | 0.032 | 0.135 | Urease inhibitor | 0.112 0.054 DBMET01449 | ||
| 0.235 | 0.136 | 0.235 | Interleukin 2 agonist | 0.199 0.192 DBMET01451 0.229 0.144 DBMET01449 | ||
| 0.113 | 0.015 | 0.215 | Estrogen agonist | 0.047 0.037 DBMET01451 0.215 0.007 DBMET01449 | DBMET01449 | |
| 0.276 | 0.178 | 0.276 | DNA polymerase beta inhibitor | |||
| 0.133 | 0.035 | 0.133 | Multidrug resistance-associated protein 1 inhibitor | 0.121 0.047 DBMET01449 | ||
| 0.108 | 0.01 | 0.121 | Estrogen receptor beta agonist | 0.033 0.023 DBMET01451 0.121 0.009 DBMET01449 | DBMET01449 | |
| 0.106 | 0.009 | 0.106 | Glutamate (mGluR6) antagonist | 0.09 0.016 DBMET01451 0.104 0.009 DBMET01449 | ||
| 0.116 | 0.019 | 0.116 | Granulocyte macrophage colony stimulating factor agonist | 0.099 0.036 DBMET01449 | ||
| 0.139 | 0.043 | 0.139 | Aminopeptidase B inhibitor | 0.104 0.062 DBMET01451 0.134 0.045 DBMET01449 | ||
| 0.149 | 0.052 | 0.162 | M18 aspartyl aminopeptidase inhibitor | 0.113 0.077 DBMET01451 0.162 0.047 DBMET01449 | DBMET01449 | |
| 0.11 | 0.014 | 0.121 | Neuraminidase (influenza) inhibitor | 0.074 0.03 DBMET01451 0.121 0.012 DBMET01449 | DBMET01449 | |
| 0.111 | 0.015 | 0.111 | Biliverdin reductase inhibitor | 0.074 0.03 DBMET01451 0.1 0.019 DBMET01449 | ||
| 0.112 | 0.017 | 0.112 | Leukotriene antagonist | 0.062 0.048 DBMET01451 0.096 0.024 DBMET01449 | ||
| 0.115 | 0.021 | 0.115 | Glycine receptor antagonist | 0.091 0.042 DBMET01449 | ||
| 0.103 | 0.01 | 0.103 | MAP kinase kinase 7 inhibitor | 0.08 0.045 DBMET01451 0.097 0.015 DBMET01449 | ||
| 0.211 | 0.118 | 0.211 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.152 | 0.059 | 0.152 | MAO inhibitor | |||
| 0.169 | 0.076 | 0.169 | 3C-like protease (Human coronavirus) inhibitor | 0.156 0.092 DBMET01449 | ||
| 0.105 | 0.014 | 0.169 | Neuraminidase inhibitor | 0.169 0.005 DBMET01451 0.107 0.013 DBMET01449 | DBMET01451 | |
| 0.116 | 0.024 | 0.12 | Bile acid receptor antagonist | 0.106 0.038 DBMET01451 0.12 0.02 DBMET01449 | DBMET01449 | |
| 0.149 | 0.06 | 0.153 | Neurotrophic factor | 0.153 0.056 DBMET01451 0.119 0.097 DBMET01449 | DBMET01451 | |
| 0.125 | 0.036 | 0.125 | Breast cancer-resistant protein inhibitor | 0.095 0.06 DBMET01449 | ||
| 0.194 | 0.106 | 0.194 | Aryl hydrocarbon receptor agonist | 0.164 0.125 DBMET01449 | ||
| 0.148 | 0.06 | 0.163 | Bone formation stimulant | 0.163 0.05 DBMET01449 | DBMET01449 | |
| 0.092 | 0.005 | 0.092 | Adenine nucleotide translocase inhibitor | 0.076 0.011 DBMET01451 0.087 0.006 DBMET01449 | ||
| 0.098 | 0.011 | 0.098 | Leukotriene B4 antagonist | 0.056 0.033 DBMET01451 0.079 0.016 DBMET01449 | ||
| 0.169 | 0.082 | 0.169 | Amyloid beta precursor protein antagonist | 0.169 0.082 DBMET01449 | ||
| 0.103 | 0.019 | 0.104 | Glycine receptor agonist | 0.103 0.019 DBMET01451 0.104 0.019 DBMET01449 | DBMET01449 | |
| 0.161 | 0.078 | 0.161 | Neurotensin receptor agonist | 0.153 0.093 DBMET01449 | ||
| 0.087 | 0.005 | 0.087 | Dopamine D5 agonist | 0.046 0.021 DBMET01451 0.075 0.007 DBMET01449 | ||
| 0.095 | 0.012 | 0.103 | Fatty acid synthase inhibitor | 0.054 0.045 DBMET01451 0.103 0.01 DBMET01449 | DBMET01449 | |
| 0.087 | 0.005 | 0.087 | Nicotinic acid receptor agonist | 0.036 0.025 DBMET01451 0.072 0.008 DBMET01449 | ||
| 0.189 | 0.109 | 0.198 | Nitric-oxide synthase stimulant | 0.172 0.148 DBMET01451 0.198 0.092 DBMET01449 | DBMET01449 | |
| 0.11 | 0.029 | 0.278 | Telomerase inhibitor | 0.278 0.007 DBMET01451 0.096 0.035 DBMET01449 | DBMET01451 | |
| 0.116 | 0.035 | 0.116 | Protein kinase C zeta inhibitor | 0.083 0.079 DBMET01449 | ||
| 0.09 | 0.012 | 0.09 | NMDA receptor subunit 3B antagonist | 0.09 0.012 DBMET01449 | ||
| 0.134 | 0.056 | 0.134 | CC chemokine 6 receptor antagonist | 0.127 0.084 DBMET01451 0.132 0.064 DBMET01449 | ||
| 0.088 | 0.011 | 0.097 | 5-Alpha-reductase inhibitor | 0.081 0.012 DBMET01451 0.097 0.01 DBMET01449 | DBMET01449 | |
| 0.094 | 0.019 | 0.094 | Protein kinase C eta inhibitor | 0.06 0.034 DBMET01449 | ||
| 0.094 | 0.021 | 0.097 | GABA B receptor agonist | 0.087 0.03 DBMET01451 0.097 0.019 DBMET01449 | DBMET01449 | |
| 0.082 | 0.01 | 0.082 | DNA helicase inhibitor | 0.055 0.036 DBMET01451 0.076 0.013 DBMET01449 | ||
| 0.092 | 0.02 | 0.092 | Peroxisome proliferator-activated receptor gamma antagonist | 0.079 0.035 DBMET01449 | ||
| 0.129 | 0.057 | 0.13 | Sphingosine 1-phosphate receptor 4 antagonist | 0.115 0.082 DBMET01451 0.13 0.056 DBMET01449 | DBMET01449 | |
| 0.11 | 0.038 | 0.11 | Thioredoxin inhibitor | 0.105 0.043 DBMET01451 0.103 0.045 DBMET01449 | ||
| 0.075 | 0.004 | 0.075 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.061 0.007 DBMET01451 0.072 0.004 DBMET01449 | ||
| 0.079 | 0.008 | 0.079 | Nicotinic acid receptor 2 agonist | 0.043 0.018 DBMET01451 0.068 0.01 DBMET01449 | ||
| 0.134 | 0.063 | 0.134 | Antibacterial (Helicobacter pylori) | 0.113 0.093 DBMET01449 | ||
| 0.13 | 0.059 | 0.346 | Cell adhesion inhibitor | 0.346 0.007 DBMET01451 0.101 0.086 DBMET01449 | DBMET01451 | |
| 0.082 | 0.011 | 0.084 | NMDA receptor subunit 3A antagonist | 0.084 0.01 DBMET01449 | DBMET01449 | |
| 0.075 | 0.004 | 0.075 | Retinoic acid receptor agonist | 0.035 0.008 DBMET01451 0.051 0.005 DBMET01449 | ||
| 0.086 | 0.017 | 0.086 | Heat shock protein 90 beta antagonist | 0.082 0.019 DBMET01449 | ||
| 0.102 | 0.033 | 0.103 | Cathepsin G inhibitor | 0.103 0.032 DBMET01449 | DBMET01449 | |
| 0.097 | 0.03 | 0.097 | Aminopeptidase I inhibitor | 0.078 0.044 DBMET01451 0.094 0.031 DBMET01449 | ||
| 0.089 | 0.023 | 0.089 | NMDA receptor glycine site agonist | 0.073 0.034 DBMET01449 | ||
| 0.078 | 0.012 | 0.078 | Dihydroorotate oxidase inhibitor | 0.068 0.019 DBMET01451 0.071 0.016 DBMET01449 | ||
| 0.082 | 0.016 | 0.082 | Carbonic anhydrase XIV inhibitor | 0.048 0.035 DBMET01449 | ||
| 0.155 | 0.089 | 0.167 | Antipruritic | 0.167 0.077 DBMET01449 | DBMET01449 | |
| 0.096 | 0.03 | 0.105 | Estrogen-related receptor beta agonist | 0.085 0.053 DBMET01451 0.105 0.019 DBMET01449 | DBMET01449 | |
| 0.083 | 0.018 | 0.083 | Thromboxane antagonist | 0.072 0.024 DBMET01449 | ||
| 0.088 | 0.024 | 0.088 | NMDA receptor agonist | 0.075 0.032 DBMET01449 | ||
| 0.082 | 0.019 | 0.164 | Alpha tubulin antagonist | 0.048 0.044 DBMET01451 0.164 0.008 DBMET01449 | DBMET01449 | |
| 0.075 | 0.013 | 0.075 | Estrogen receptor alpha agonist | 0.058 0.015 DBMET01449 | ||
| 0.072 | 0.011 | 0.072 | Dihydroorotase inhibitor | 0.043 0.033 DBMET01451 0.061 0.015 DBMET01449 | ||
| 0.066 | 0.004 | 0.066 | Retinoid X receptor antagonist | 0.053 0.01 DBMET01451 0.056 0.008 DBMET01449 | ||
| 0.083 | 0.021 | 0.083 | Carbonic anhydrase VB inhibitor | 0.073 0.026 DBMET01449 | ||
| 0.121 | 0.059 | 0.121 | Caspase 3 inhibitor | 0.115 0.067 DBMET01449 | ||
| 0.066 | 0.007 | 0.066 | Guanylate cyclase inhibitor | 0.04 0.034 DBMET01451 0.062 0.009 DBMET01449 | ||
| 0.101 | 0.042 | 0.101 | Glutamate release inhibitor | 0.086 0.072 DBMET01451 0.098 0.046 DBMET01449 | ||
| 0.094 | 0.035 | 0.094 | NMDA 2 receptor antagonist | |||
| 0.088 | 0.031 | 0.089 | Carbonic anhydrase VA inhibitor | 0.089 0.031 DBMET01449 | DBMET01449 | |
| 0.128 | 0.07 | 0.129 | Vanilloid 1 agonist | 0.129 0.068 DBMET01451 0.129 0.069 DBMET01449 | DBMET01449 | |
| 0.08 | 0.023 | 0.08 | Aldose reductase inhibitor | 0.074 0.025 DBMET01449 | ||
| 0.07 | 0.014 | 0.07 | Pregnane X receptor antagonist | 0.068 0.016 DBMET01451 0.07 0.014 DBMET01449 | ||
| 0.075 | 0.018 | 0.075 | Thromboxane A2 antagonist | 0.066 0.024 DBMET01449 | ||
| 0.086 | 0.032 | 0.087 | Carbonic anhydrase V inhibitor | 0.087 0.032 DBMET01449 | DBMET01449 | |
| 0.063 | 0.009 | 0.063 | DNA gyrase subunit A inhibitor | 0.057 0.012 DBMET01449 | ||
| 0.118 | 0.064 | 0.12 | Transcription factor STAT6 inhibitor | 0.12 0.06 DBMET01449 | DBMET01449 | |
| 0.066 | 0.013 | 0.066 | Factor III inhibitor | 0.05 0.034 DBMET01451 0.06 0.018 DBMET01449 | ||
| 0.073 | 0.02 | 0.073 | Dihydroorotate dehydrogenase inhibitor | 0.058 0.03 DBMET01449 | ||
| 0.057 | 0.005 | 0.057 | Retinoid X beta receptor agonist | 0.021 0.014 DBMET01451 0.033 0.007 DBMET01449 | ||
| 0.095 | 0.043 | 0.095 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.091 0.048 DBMET01449 | ||
| 0.073 | 0.022 | 0.077 | Heme oxygenase stimulant | 0.072 0.023 DBMET01451 0.077 0.018 DBMET01449 | DBMET01449 | |
| 0.075 | 0.024 | 0.075 | Acyl-CoA dehydrogenase inhibitor | 0.051 0.041 DBMET01451 0.068 0.028 DBMET01449 | ||
| 0.056 | 0.006 | 0.056 | NMDA 2D receptor antagonist | 0.03 0.016 DBMET01451 0.05 0.007 DBMET01449 | ||
| 0.055 | 0.005 | 0.055 | Retinoid X gamma receptor agonist | 0.022 0.017 DBMET01451 0.034 0.009 DBMET01449 | ||
| 0.053 | 0.004 | 0.053 | Retinoic acid alpha receptor antagonist | 0.034 0.005 DBMET01451 0.045 0.004 DBMET01449 | ||
| 0.076 | 0.027 | 0.076 | NMDA 2C receptor antagonist | 0.066 0.037 DBMET01449 | ||
| 0.075 | 0.027 | 0.075 | Maillard reaction inhibitor | 0.063 0.033 DBMET01449 | ||
| 0.052 | 0.004 | 0.052 | Retinoic acid receptor antagonist | 0.029 0.006 DBMET01451 0.042 0.004 DBMET01449 | ||
| 0.066 | 0.019 | 0.066 | Leukotriene C antagonist | 0.054 0.047 DBMET01451 0.061 0.026 DBMET01449 | ||
| 0.076 | 0.03 | 0.078 | Aromatase inhibitor | 0.061 0.041 DBMET01451 0.078 0.028 DBMET01449 | DBMET01449 | |
| 0.051 | 0.004 | 0.051 | Retinoic acid beta receptor agonist | 0.027 0.007 DBMET01451 0.034 0.005 DBMET01449 | ||
| 0.05 | 0.005 | 0.055 | Glutamate (mGluR3) agonist | 0.046 0.006 DBMET01451 0.055 0.004 DBMET01449 | DBMET01449 | |
| 0.051 | 0.006 | 0.051 | Retinoid X alpha receptor antagonist | 0.039 0.016 DBMET01451 0.042 0.013 DBMET01449 | ||
| 0.07 | 0.024 | 0.073 | NMDA 2A receptor antagonist | 0.073 0.023 DBMET01449 | DBMET01449 | |
| 0.077 | 0.031 | 0.102 | Glutamate (mGluR7) antagonist | 0.068 0.046 DBMET01451 0.102 0.01 DBMET01449 | DBMET01449 | |
| 0.052 | 0.007 | 0.052 | 5-Alpha-reductase 2 inhibitor | 0.025 0.01 DBMET01451 0.043 0.008 DBMET01449 | ||
| 0.052 | 0.007 | 0.052 | Protein kinase (CK2) beta inhibitor | 0.033 0.023 DBMET01451 0.04 0.012 DBMET01449 | ||
| 0.056 | 0.012 | 0.056 | Nerve growth factor antagonist | |||
| 0.15 | 0.106 | 0.15 | Platelet adhesion inhibitor | 0.144 0.113 DBMET01449 | ||
| 0.059 | 0.015 | 0.081 | Urate transporter 1 inhibitor | 0.081 0.008 DBMET01449 | DBMET01449 | |
| 0.126 | 0.082 | 0.126 | Sphingosine 1-phosphate receptor 2 antagonist | 0.114 0.112 DBMET01449 | ||
| 0.078 | 0.034 | 0.078 | Protein kinase C beta inhibitor | 0.068 0.052 DBMET01451 0.065 0.058 DBMET01449 | ||
| 0.053 | 0.01 | 0.056 | Glutamate (mGluR8) agonist | 0.047 0.014 DBMET01451 0.056 0.009 DBMET01449 | DBMET01449 | |
| 0.073 | 0.03 | 0.073 | TRPA1 antagonist | |||
| 0.136 | 0.093 | 0.19 | Thrombolytic | 0.19 0.057 DBMET01451 | DBMET01451 | |
| 0.046 | 0.003 | 0.046 | Retinoic acid beta receptor antagonist | 0.018 0.005 DBMET01451 0.028 0.004 DBMET01449 | ||
| 0.121 | 0.079 | 0.121 | Papain-like protease (SARS coronavirus) inhibitor | 0.115 0.095 DBMET01449 | ||
| 0.081 | 0.04 | 0.081 | Peroxisome proliferator-activated receptor gamma agonist | |||
| 0.048 | 0.007 | 0.048 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.048 0.007 DBMET01449 | ||
| 0.086 | 0.044 | 0.086 | Catalase inhibitor | 0.078 0.049 DBMET01449 | ||
| 0.049 | 0.008 | 0.049 | Purinergic P2Y14 antagonist | 0.03 0.02 DBMET01451 0.047 0.008 DBMET01449 | ||
| 0.163 | 0.124 | 0.164 | Hypolipemic | 0.164 0.124 DBMET01449 | DBMET01449 | |
| 0.097 | 0.058 | 0.097 | Phosphodiesterase 6D inhibitor | |||
| 0.052 | 0.014 | 0.058 | GABA uptake inhibitor | 0.037 0.031 DBMET01451 0.058 0.011 DBMET01449 | DBMET01449 | |
| 0.062 | 0.025 | 0.062 | Thromboxane synthase inhibitor | 0.059 0.029 DBMET01449 | ||
| 0.06 | 0.023 | 0.06 | Lysophosphatidic acid 3 receptor antagonist | 0.047 0.041 DBMET01449 | ||
| 0.06 | 0.024 | 0.06 | Plasminogen activator inhibitor antagonist | 0.05 0.032 DBMET01449 | ||
| 0.069 | 0.033 | 0.069 | Prostaglandin F2 alpha antagonist | 0.06 0.047 DBMET01449 | ||
| 0.117 | 0.081 | 0.172 | Acetylcholinesterase inhibitor | 0.172 0.043 DBMET01451 | DBMET01451 | |
| 0.054 | 0.019 | 0.058 | Neuraminidase (Influenza A) inhibitor | 0.044 0.034 DBMET01451 0.058 0.014 DBMET01449 | DBMET01449 | |
| 0.057 | 0.021 | 0.057 | Carbonic anhydrase VII inhibitor | 0.046 0.033 DBMET01449 | ||
| 0.069 | 0.034 | 0.069 | Prostaglandin EP2 antagonist | 0.066 0.036 DBMET01449 | ||
| 0.039 | 0.004 | 0.039 | Retinoic acid gamma receptor agonist | 0.029 0.007 DBMET01451 0.035 0.005 DBMET01449 | ||
| 0.126 | 0.092 | 0.126 | Cyclooxygenase inhibitor | |||
| 0.048 | 0.014 | 0.049 | Glutamate (mGluR3) antagonist | 0.034 0.029 DBMET01451 0.049 0.013 DBMET01449 | DBMET01449 | |
| 0.064 | 0.03 | 0.064 | Bcl-xL inhibitor | |||
| 0.059 | 0.025 | 0.059 | Phosphorylase inhibitor | |||
| 0.038 | 0.005 | 0.04 | Vanilloid 2 agonist | 0.04 0.004 DBMET01451 0.04 0.004 DBMET01449 | DBMET01449 | |
| 0.13 | 0.097 | 0.13 | Thiol protease inhibitor | |||
| 0.149 | 0.117 | 0.149 | Psychostimulant | 0.139 0.126 DBMET01449 | ||
| 0.041 | 0.01 | 0.062 | Protein 30S ribosomal subunit inhibitor | 0.062 0.006 DBMET01451 0.042 0.009 DBMET01449 | DBMET01451 | |
| 0.085 | 0.055 | 0.085 | 3C-Like protease (SARS coronavirus) inhibitor | 0.084 0.057 DBMET01449 | ||
| 0.033 | 0.004 | 0.033 | Retinoic acid receptor gamma antagonist | 0.015 0.005 DBMET01451 0.026 0.004 DBMET01449 | ||
| 0.046 | 0.017 | 0.046 | Arginase inhibitor | 0.041 0.022 DBMET01449 | ||
| 0.036 | 0.007 | 0.036 | Nicotinic acid receptor 2 antagonist | 0.025 0.021 DBMET01451 0.036 0.007 DBMET01449 | ||
| 0.074 | 0.045 | 0.074 | Phospholipase D inhibitor | 0.067 0.06 DBMET01449 | ||
| 0.055 | 0.027 | 0.055 | Squalene epoxidase inhibitor | 0.05 0.034 DBMET01449 | ||
| 0.04 | 0.012 | 0.04 | Leukotriene B4 receptor 1 antagonist | 0.035 0.014 DBMET01449 | ||
| 0.035 | 0.007 | 0.035 | Retinoid X gamma receptor antagonist | 0.028 0.017 DBMET01451 0.031 0.011 DBMET01449 | ||
| 0.036 | 0.008 | 0.037 | Prostaglandin H2 antagonist | 0.037 0.008 DBMET01449 | DBMET01449 | |
| 0.112 | 0.085 | 0.112 | M17 leucyl aminopeptidase inhibitor | |||
| 0.04 | 0.013 | 0.04 | Prostaglandin agonist | 0.035 0.017 DBMET01451 0.037 0.015 DBMET01449 | ||
| 0.036 | 0.01 | 0.036 | Prostaglandin EP2 agonist | 0.035 0.01 DBMET01449 | ||
| 0.045 | 0.018 | 0.05 | Farnesoid X receptor agonist | 0.05 0.014 DBMET01449 | DBMET01449 | |
| 0.049 | 0.022 | 0.053 | Glutamate (mGluR group III) antagonist | 0.053 0.018 DBMET01449 | DBMET01449 | |
| 0.033 | 0.007 | 0.033 | Leukotriene B4 receptor 2 antagonist | 0.024 0.014 DBMET01451 0.03 0.009 DBMET01449 | ||
| 0.045 | 0.019 | 0.045 | TRPM8 blocker | |||
| 0.029 | 0.004 | 0.029 | Retinoid X beta receptor antagonist | 0.019 0.018 DBMET01451 0.023 0.01 DBMET01449 | ||
| 0.098 | 0.073 | 0.098 | Toll-Like receptor 4 antagonist | |||
| 0.082 | 0.057 | 0.082 | Glutathione S-transferase inhibitor | 0.077 0.066 DBMET01449 | ||
| 0.043 | 0.018 | 0.043 | Leukotriene C4 antagonist | 0.039 0.026 DBMET01449 | ||
| 0.056 | 0.031 | 0.064 | Heparanase inhibitor | 0.064 0.018 DBMET01449 | DBMET01449 | |
| 0.029 | 0.004 | 0.029 | Antibiotic Anthracycline-like | 0.02 0.01 DBMET01451 0.024 0.006 DBMET01449 | ||
| 0.028 | 0.005 | 0.03 | Nicotinic acid receptor 1 antagonist | 0.02 0.009 DBMET01451 0.03 0.004 DBMET01449 | DBMET01449 | |
| 0.039 | 0.015 | 0.039 | Catechol O-methyltransferase inhibitor | 0.035 0.019 DBMET01449 | ||
| 0.026 | 0.003 | 0.026 | Antibiotic Tetracycline-like | 0.024 0.003 DBMET01451 0.026 0.003 DBMET01449 | ||
| 0.092 | 0.069 | 0.092 | Sphingomyelinase inhibitor | |||
| 0.031 | 0.009 | 0.031 | Glutamate (mGluR1) agonist | |||
| 0.049 | 0.027 | 0.049 | Adenylate cyclase 1 inhibitor | |||
| 0.054 | 0.032 | 0.054 | Prostaglandin E2 antagonist | 0.044 0.043 DBMET01449 | ||
| 0.036 | 0.015 | 0.036 | Protein kinase C beta I inhibitor | 0.035 0.019 DBMET01449 | ||
| 0.042 | 0.02 | 0.053 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.053 0.014 DBMET01449 | DBMET01449 | |
| 0.044 | 0.023 | 0.044 | Kainate receptor agonist | 0.043 0.024 DBMET01449 | ||
| 0.047 | 0.026 | 0.047 | Leukocyte elastase inhibitor | 0.044 0.028 DBMET01449 | ||
| 0.039 | 0.018 | 0.039 | Glutamate (mGluR8) antagonist | 0.034 0.028 DBMET01451 0.038 0.02 DBMET01449 | ||
| 0.077 | 0.057 | 0.077 | Interferon agonist | 0.071 0.069 DBMET01451 | ||
| 0.046 | 0.026 | 0.046 | Glutamate (mGluR4) antagonist | 0.041 0.036 DBMET01449 | ||
| 0.039 | 0.019 | 0.043 | Somatostatin 5 antagonist | 0.043 0.016 DBMET01449 | DBMET01449 | |
| 0.059 | 0.04 | 0.059 | Ryanodine receptor antagonist | 0.056 0.053 DBMET01449 | ||
| 0.063 | 0.045 | 0.064 | Transcription factor RelA inhibitor | 0.064 0.042 DBMET01449 | DBMET01449 | |
| 0.1 | 0.081 | 0.1 | Interleukin 1b antagonist | |||
| 0.064 | 0.046 | 0.064 | Beta 3 adrenoreceptor antagonist | |||
| 0.027 | 0.009 | 0.042 | 5-Alpha-reductase 1 inhibitor | 0.042 0.008 DBMET01449 | DBMET01449 | |
| 0.049 | 0.032 | 0.049 | Glucose-6-phosphate isomerase inhibitor | 0.046 0.036 DBMET01449 | ||
| 0.043 | 0.026 | 0.043 | Liver X receptor alpha agonist | |||
| 0.077 | 0.061 | 0.077 | Adrenaline agonist | |||
| 0.037 | 0.021 | 0.073 | RNA-directed RNA polymerase inhibitor | 0.073 0.007 DBMET01449 | DBMET01449 | |
| 0.082 | 0.066 | 0.121 | Transcription factor NF kappa B stimulant | 0.121 0.025 DBMET01451 0.082 0.066 DBMET01449 | DBMET01451 | |
| 0.063 | 0.047 | 0.063 | Protease 3C (Human rhinovirus) inhibitor | 0.062 0.049 DBMET01449 | ||
| 0.048 | 0.033 | 0.048 | Peroxisome proliferator-activated receptor alpha agonist | |||
| 0.024 | 0.009 | 0.024 | Neuraminidase (Influenza B) inhibitor | 0.022 0.012 DBMET01449 | ||
| 0.036 | 0.022 | 0.036 | Fumarate hydratase inhibitor | 0.034 0.024 DBMET01449 | ||
| 0.043 | 0.029 | 0.043 | GABA B receptor antagonist | |||
| 0.035 | 0.021 | 0.062 | Purinergic P2Y2 antagonist | 0.062 0.007 DBMET01449 | DBMET01449 | |
| 0.083 | 0.07 | 0.083 | ATPase (Vacuolar H+) inhibitor | |||
| 0.028 | 0.014 | 0.028 | NMDA receptor glycine site antagonist | |||
| 0.103 | 0.09 | 0.103 | Interleukin 8 antagonist | |||
| 0.071 | 0.059 | 0.077 | Na+ K+ transporting ATPase inhibitor | 0.069 0.061 DBMET01451 0.077 0.054 DBMET01449 | DBMET01449 | |
| 0.042 | 0.03 | 0.042 | Dopamine D5 antagonist | |||
| 0.045 | 0.033 | 0.045 | Purinergic P2X4 antagonist | |||
| 0.05 | 0.039 | 0.05 | Glucose-6-phosphate translocase inhibitor | 0.049 0.04 DBMET01449 | ||
| 0.025 | 0.014 | 0.025 | Prostaglandin E2 agonist | 0.023 0.016 DBMET01449 | ||
| 0.019 | 0.009 | 0.019 | Prostaglandin EP4 agonist | |||
| 0.024 | 0.014 | 0.024 | Beta 1 adrenoreceptor agonist | |||
| 0.031 | 0.022 | 0.071 | HCV NS5B polymerase inhibitor | 0.071 0.007 DBMET01449 | DBMET01449 | |
| 0.029 | 0.02 | 0.029 | Liver X receptor beta antagonist | |||
| 0.027 | 0.018 | 0.027 | Kynurenine 3 monooxygenase inhibitor | |||
| 0.049 | 0.041 | 0.049 | Ornithine carbamoyltransferase inhibitor | 0.046 0.044 DBMET01449 | ||
| 0.105 | 0.097 | 0.105 | Cathepsin H inhibitor | |||
| 0.023 | 0.015 | 0.023 | Prostaglandin F2 alpha agonist | 0.022 0.017 DBMET01449 | ||
| 0.044 | 0.036 | 0.044 | Adenosine deaminase inhibitor | |||
| 0.105 | 0.098 | 0.105 | Cyclooxygenase 2 inhibitor | |||
| 0.038 | 0.031 | 0.038 | Kainate receptor antagonist | |||
| 0.055 | 0.049 | 0.058 | Androgen agonist | 0.058 0.044 DBMET01449 | DBMET01449 | |
| 0.013 | 0.007 | 0.013 | Thrombopoietin agonist | |||
| 0.031 | 0.026 | 0.033 | Estrogen-related receptor beta antagonist | 0.033 0.021 DBMET01449 | DBMET01449 | |
| 0.019 | 0.014 | 0.019 | Prostaglandin EP1 antagonist | |||
| 0.044 | 0.038 | 0.044 | Beta adrenoreceptor agonist | |||
| 0.033 | 0.029 | 0.036 | Calcium-independent phospholipase A2 inhibitor | 0.036 0.018 DBMET01449 | DBMET01449 | |
| 0.012 | 0.008 | 0.013 | Glutamate (mGluR6) agonist | 0.013 0.007 DBMET01449 | DBMET01449 | |
| 0.076 | 0.072 | 0.076 | Histamine N-methyltransferase inhibitor | |||
| 0.024 | 0.021 | 0.024 | Prostaglandin EP4 antagonist | |||
| 0.014 | 0.011 | 0.014 | Egl nine homolog 1 inhibitor | |||
| 0.025 | 0.023 | 0.025 | Uridine phosphorylase inhibitor | |||
| 0.109 | 0.107 | 0.109 | Interleukin 1 antagonist | |||
| 0.008 | 0.006 | 0.008 | Mannitol 2-dehydrogenase inhibitor | 0.008 0.006 DBMET01449 | ||
| 0.078 | 0.077 | 0.078 | MAO B inhibitor | |||
| 0.02 | 0.02 | 0.023 | Dopamine D1 agonist | 0.023 0.015 DBMET01449 | DBMET01449 | |
| 0.018 | 0.019 | 0.036 | Estrone sulfatase inhibitor | 0.036 0.009 DBMET01449 | DBMET01449 | |
| 0.053 | 0.057 | 0.056 | Lipocortins synthesis agonist | 0.056 0.046 DBMET01449 | DBMET01449 | |
| 0.062 | 0.068 | 0.066 | MDM2 inhibitor | 0.066 0.052 DBMET01449 | DBMET01449 | |
| 0.029 | 0.038 | 0.039 | Cathepsin L2 inhibitor | 0.039 0.029 DBMET01449 | DBMET01449 | |
| 0.051 | 0.064 | 0.057 | DNA gyrase inhibitor | 0.057 0.053 DBMET01449 | DBMET01449 | |
| 0.057 | 0.071 | 0.064 | Calcium channel P-type blocker | 0.064 0.044 DBMET01449 | DBMET01449 | |
| 0.02 | 0.034 | 0.025 | Calcium-sensing receptor agonist | 0.025 0.021 DBMET01449 | DBMET01449 | |
| 0.039 | 0.054 | 0.048 | Aldosterone antagonist | 0.048 0.032 DBMET01449 | DBMET01449 | |
| 0.066 | 0.083 | 0.082 | Androgen antagonist | 0.082 0.063 DBMET01449 | DBMET01449 | |
| 0.027 | 0.058 | 0.049 | Purinergic P2Y antagonist | 0.049 0.027 DBMET01449 | DBMET01449 | |
| 0.043 | 0.093 | 0.072 | Transcription factor AP-1 inhibitor | 0.072 0.028 DBMET01449 | DBMET01449 | |
| 0.061 | 0.117 | 0.083 | Protein kinase C delta inhibitor | 0.083 0.072 DBMET01451 | DBMET01451 | |
| 0.066 | 0.132 | 0.124 | Vanilloid agonist | 0.124 0.016 DBMET01451 | DBMET01451 | |
| 0.119 | 0.188 | 0.227 | Platelet antagonist | 0.227 0.084 DBMET01451 | DBMET01451 | |
| 0.055 | 0.126 | 0.076 | Antineoplastic alkaloid | 0.076 0.071 DBMET01449 | DBMET01449 | |
| 0.108 | 0.181 | 0.309 | Antimitotic | 0.309 0.041 DBMET01449 | DBMET01449 | |
| 0.054 | 0.131 | 0.27 | Cell adhesion molecule inhibitor | 0.27 0.005 DBMET01451 | DBMET01451 | |
| 0.083 | 0.174 | 0.129 | Cholinergic | 0.129 0.097 DBMET01451 | DBMET01451 | |
| 0.047 | 0.161 | 0.063 | Prolactin release inhibitor | 0.059 0.056 DBMET01451 0.063 0.04 DBMET01449 | DBMET01449 | |
| 0.069 | 0.21 | 0.109 | Histone deacetylase SIRT1 inhibitor | 0.109 0.106 DBMET01449 | DBMET01449 | |
| 0.038 | 0.364 | 0.122 | Anticoagulant | 0.122 0.11 DBMET01451 | DBMET01451 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |